BioStock: RhoVac brings in Stifel as transaction advisor for RV001

Biotech company RhoVac has started the autumn by reaching several important milestones in its work with drug candidate RV001. Next year’s readout of  the phase IIb study BRaVac is rapidly approaching and the company is now contracting Investment Bank Stifel Nicolaus Europe as an advisor on the subsequent exit or partnership process. BioStock spoke to RhoVac’s CEO Anders Månsson to find out more.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/10/rhovac-brings-in-stifel-as-transaction-advisor-for-rv001/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se